PCSK9 and familial hypercholesterolemia: These findings supported that all four PCSK9 monoclonal antibodies provided new options for the treatment of hypercholesterolemia and positioned ongericimab 150 mg Q2W as a clinically optimal PCSK9 inhibitor with robust lipid‐lowering capacity.